# Efinopegdutide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efinopegdutide

> Efinopegdutide, sponsored by Merck & Co., Inc. (MRK): 5 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | efinopegdutide |
| Codes | MK-6024, HM12525A, JNJ-64565111 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Non-alcoholic Fatty Liver Disease](https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease), [Metabolic Dysfunction-Associated Steatotic Liver Disease](https://sec-api.dev/indications/metabolic-dysfunction-associated-steatotic-liver-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 27, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06482112 (Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-01." https://clinicaltrials.gov/study/NCT06482112

### December 29, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05877547

### June 1, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06482112 (Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-01." https://clinicaltrials.gov/study/NCT06482112?tab=results

### August 3, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06465186 (A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06465186

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06465186 (A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06465186

## Same indication

- [Aln-cideb](https://sec-api.dev/pdufa/aln-cideb) (REGN)
- [Efimosfermin alfa](https://sec-api.dev/pdufa/efimosfermin-alfa) (GSK)
- [GSK4532990](https://sec-api.dev/pdufa/gsk4532990) (GSK)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efinopegdutide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Efinopegdutide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efinopegdutide

```bibtex
@misc{secapidev_pdufa_efinopegdutide_20261116,
  title        = {Efinopegdutide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efinopegdutide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efinopegdutide_20261116","title":"Efinopegdutide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efinopegdutide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
